Skip to content

Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study

Early Detection of Pre-malignant and Malignant Conditions in the Colon by Means of Fluorescence Endoscopy Using Local and Oral Sensitisation With Hexaminolevulinate (HAL) - a Dose Finding Study

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00285701
Enrollment
38
Registered
2006-02-02
Start date
2006-07-31
Completion date
2008-03-31
Last updated
2010-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

Patients referred for colon inspection (colonoscopy) due to suspicion of colon polyps/cancer will receive local administration of hexaminolevulinate (HAL) prior to colon inspection. Blue light illumination will induce red fluorescence of polyps and tumours, improving detection of the polyps and tumors. Different HAL doses will be tested to find the optimal image conditions. Tolerability measurements will be performed to ensure patient safety.

Detailed description

Colonoscopy is regarded as the gold standard for diagnosis of colorectal cancer. The sensitivity is uncertain but proposed to be (75-95%), however flat adenomas which are easily missed, are often not recognised. Fluorescence imaging may increase the sensitivity of standard white light colonoscopy by identifying more polyps and flat adenomas which will make the resection of adenomas more complete. In this study hexaminolevulinate (HAL) will be administered locally as a photosensitiser, using different doses to find the optimal imaging conditions as well as making patient safety assessments. Both standard white light and blue light (fluorescence) inspection will be performed.

Interventions

Sponsors

KARL STORZ Endoscopy-America, Inc.
CollaboratorINDUSTRY
Photocure
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Patients with suspicion of colorectal cancer * Written informed consent * Data protection consent * 18-85 years

Exclusion criteria

* Liver cirrhosis * Hepatitis * Abnormal liver function * Porphyria * Patient non-compliance * Coagulation disorder * Contraindication to colonoscopy * Pregnancy and lactation * Participation in another study

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026